WO1995006717A3 - Methods of suppressing graft rejection - Google Patents

Methods of suppressing graft rejection Download PDF

Info

Publication number
WO1995006717A3
WO1995006717A3 PCT/US1994/009957 US9409957W WO9506717A3 WO 1995006717 A3 WO1995006717 A3 WO 1995006717A3 US 9409957 W US9409957 W US 9409957W WO 9506717 A3 WO9506717 A3 WO 9506717A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
graft rejection
transformed
tissue cells
suppressing graft
Prior art date
Application number
PCT/US1994/009957
Other languages
French (fr)
Other versions
WO1995006717A2 (en
Inventor
John F Warner
Carol-Gay Anderson
Douglas J Jolly
Thomas W Dubensky Jr
Carlos E Ibanez
Michael J Irwin
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to EP94927332A priority Critical patent/EP0716691A1/en
Priority to AU76813/94A priority patent/AU7681394A/en
Priority to JP7508294A priority patent/JPH09503656A/en
Publication of WO1995006717A2 publication Critical patent/WO1995006717A2/en
Publication of WO1995006717A3 publication Critical patent/WO1995006717A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tissue cells of an animal transformed with a recombinant vector construct which (a) directs the expression of a protein or active portion thereof; (b) transcribes an antisense message; or (c) transcribes a ribozyme capable of inhibiting MHC antigen presentation are provided. In a related aspect, the cells are transformed with two or more of such proteins, antisense or ribozymes, or combinations thereof. The tissue cells are particularly useful within methods for suppressing graft rejection. Pharmaceutical compositions comprising such transformed tissue cells are also provided.
PCT/US1994/009957 1993-09-03 1994-09-02 Methods of suppressing graft rejection WO1995006717A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP94927332A EP0716691A1 (en) 1993-09-03 1994-09-02 Methods of suppressing graft rejection
AU76813/94A AU7681394A (en) 1993-09-03 1994-09-02 Methods of suppressing graft rejection
JP7508294A JPH09503656A (en) 1993-09-03 1994-09-02 How to suppress graft rejection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11682793A 1993-09-03 1993-09-03
US08/116,827 1993-09-03

Publications (2)

Publication Number Publication Date
WO1995006717A2 WO1995006717A2 (en) 1995-03-09
WO1995006717A3 true WO1995006717A3 (en) 1995-04-06

Family

ID=22369470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009957 WO1995006717A2 (en) 1993-09-03 1994-09-02 Methods of suppressing graft rejection

Country Status (5)

Country Link
EP (1) EP0716691A1 (en)
JP (1) JPH09503656A (en)
AU (1) AU7681394A (en)
CA (1) CA2158933A1 (en)
WO (1) WO1995006717A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6657996A (en) * 1995-07-18 1997-02-18 Guido Krupp Ribozymes for the selective inhibition of expression by mhc llele genes, and drugs containing such ribozymes
WO1998031813A1 (en) * 1997-01-17 1998-07-23 Roche Diagnostics Gmbh Inhibitors of antigen presentation by mhc class i molecules
US20030134809A1 (en) * 2001-12-17 2003-07-17 Isis Pharmaceuticals Inc. Antisense modulation of ABC transporter MHC 1 expression

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005855A1 (en) * 1987-12-15 1989-06-29 Cogent Limited Human cytomegalovirus protein
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
WO1992014829A1 (en) * 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
WO1993014769A1 (en) * 1992-01-31 1993-08-05 The Regents Of The University Of California Method for making universal donor cells
EP0601585A2 (en) * 1992-12-09 1994-06-15 Enzo Therapeutics, Inc. Nucleic acid construct for inhibiting or regulating the functions of an immuno response gene, method utilizing the same and immunologically compatible system containing the same
WO1994016065A1 (en) * 1992-12-31 1994-07-21 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005855A1 (en) * 1987-12-15 1989-06-29 Cogent Limited Human cytomegalovirus protein
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
WO1992014829A1 (en) * 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
WO1993014769A1 (en) * 1992-01-31 1993-08-05 The Regents Of The University Of California Method for making universal donor cells
EP0601585A2 (en) * 1992-12-09 1994-06-15 Enzo Therapeutics, Inc. Nucleic acid construct for inhibiting or regulating the functions of an immuno response gene, method utilizing the same and immunologically compatible system containing the same
WO1994016065A1 (en) * 1992-12-31 1994-07-21 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. BROWNE ET AL.: "A complex between the MHC class I homologue encoded by human CMV and beta2 -microglobulin", NATURE, vol. 347, 25 October 1990 (1990-10-25), LONDON, pages 770 - 772 *

Also Published As

Publication number Publication date
WO1995006717A2 (en) 1995-03-09
JPH09503656A (en) 1997-04-15
EP0716691A1 (en) 1996-06-19
CA2158933A1 (en) 1995-03-09
AU7681394A (en) 1995-03-22

Similar Documents

Publication Publication Date Title
GR3023329T3 (en) Plasma and recombinant protein formulations in low ionic strength media
DK0870022T3 (en) Immunostimulatory composition and method
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO1997014806A3 (en) Delivery of biologically active polypeptides
EP2278021A3 (en) Expression vectors, transfection systems, and method of use thereof
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
WO1995006718A3 (en) Methods of suppressing autoimmune response
WO2001096392A8 (en) 22109, a novel human thioredoxin family member and uses thereof
WO1995006717A3 (en) Methods of suppressing graft rejection
WO2002002760A3 (en) 25869, a human carboxylesterase and uses thereof
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
WO2000052164A3 (en) Potassium channel molecules and uses therefor
WO1995006744A3 (en) Methods of suppressing immune response by gene therapy
NO961423D0 (en) Oligopeptides derived from C-reactive protein fragments
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2001068857A3 (en) 18615 and 48003, human ion channels and uses therefor
WO2001032872A3 (en) Twik potassium channel molecules and uses therefor
WO2001079473A3 (en) 21953, a human prolyl oligopeptidase family member and uses thereof
WO2002024743A3 (en) 55063, a human nmda family member and uses thereof
WO2001090146A3 (en) 57256 and 58289, human transporters and uses thereof
WO2002026983A3 (en) 56115, a novel human twik potassium channel and uses therefor
WO2001077329A8 (en) Human twik molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2158933

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994927332

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994927332

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994927332

Country of ref document: EP